Aspirin plus ticlopidine prevented experimental endocarditis due to Enterococcus faecalis and Streptococcus gallolyticus. 2015

Tiago Rafael Veloso, and Frank Oechslin, and Yok-Ai Que, and Philippe Moreillon, and José Manuel Entenza, and Stefano Mancini
Department of Fundamental Microbiology, University of Lausanne, CH-1015 Lausanne, Switzerland.

Enterococcus faecalis and Streptococcus gallolyticus cause infective endocarditis (IE), which can originate from the continuous release or translocation of low bacterial numbers into the bloodstream. In this context, IE cannot be prevented with antibiotics. We previously demonstrated that aspirin plus ticlopidine protected rats from IE due to S. gordonii and Staphylococcus aureus. Here we showed that aspirin plus ticlopidine significantly reduced vegetation weight and protected 73 and 64% rats (P < 0.005) from IE due to E. faecalis and S. gallolyticus, respectively. These results further support the potential use of aspirin plus ticlopidine for a global prevention of IE in high-risk patients.

UI MeSH Term Description Entries
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004697 Endocarditis, Bacterial Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use. Bacterial Endocarditides,Bacterial Endocarditis,Endocarditides, Bacterial
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001241 Aspirin The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) Acetylsalicylic Acid,2-(Acetyloxy)benzoic Acid,Acetysal,Acylpyrin,Aloxiprimum,Colfarit,Dispril,Easprin,Ecotrin,Endosprin,Magnecyl,Micristin,Polopirin,Polopiryna,Solprin,Solupsan,Zorprin,Acid, Acetylsalicylic
D013291 Streptococcus A genus of gram-positive, coccoid bacteria whose organisms occur in pairs or chains. No endospores are produced. Many species exist as commensals or parasites on man or animals with some being highly pathogenic. A few species are saprophytes and occur in the natural environment.
D013293 Enterococcus faecalis A species of gram-positive, coccoid bacteria commonly isolated from clinical specimens and the human intestinal tract. Most strains are nonhemolytic. Streptococcus Group D,Streptococcus faecalis
D013988 Ticlopidine An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES. 53-32C,Ticlid,Ticlodix,Ticlodone,Ticlopidine Hydrochloride,53 32C,5332C,Hydrochloride, Ticlopidine
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Tiago Rafael Veloso, and Frank Oechslin, and Yok-Ai Que, and Philippe Moreillon, and José Manuel Entenza, and Stefano Mancini
January 2019, Frontiers in cellular and infection microbiology,
Tiago Rafael Veloso, and Frank Oechslin, and Yok-Ai Que, and Philippe Moreillon, and José Manuel Entenza, and Stefano Mancini
April 2022, Journal of clinical medicine,
Tiago Rafael Veloso, and Frank Oechslin, and Yok-Ai Que, and Philippe Moreillon, and José Manuel Entenza, and Stefano Mancini
February 2006, Antimicrobial agents and chemotherapy,
Tiago Rafael Veloso, and Frank Oechslin, and Yok-Ai Que, and Philippe Moreillon, and José Manuel Entenza, and Stefano Mancini
July 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Tiago Rafael Veloso, and Frank Oechslin, and Yok-Ai Que, and Philippe Moreillon, and José Manuel Entenza, and Stefano Mancini
March 1999, Antimicrobial agents and chemotherapy,
Tiago Rafael Veloso, and Frank Oechslin, and Yok-Ai Que, and Philippe Moreillon, and José Manuel Entenza, and Stefano Mancini
January 2011, Acta medica portuguesa,
Tiago Rafael Veloso, and Frank Oechslin, and Yok-Ai Que, and Philippe Moreillon, and José Manuel Entenza, and Stefano Mancini
January 2023, Pediatrics international : official journal of the Japan Pediatric Society,
Tiago Rafael Veloso, and Frank Oechslin, and Yok-Ai Que, and Philippe Moreillon, and José Manuel Entenza, and Stefano Mancini
February 1995, Postgraduate medical journal,
Tiago Rafael Veloso, and Frank Oechslin, and Yok-Ai Que, and Philippe Moreillon, and José Manuel Entenza, and Stefano Mancini
January 1999, Antimicrobial agents and chemotherapy,
Tiago Rafael Veloso, and Frank Oechslin, and Yok-Ai Que, and Philippe Moreillon, and José Manuel Entenza, and Stefano Mancini
June 1987, The Journal of infectious diseases,
Copied contents to your clipboard!